Tilray Brands Inc. (NASDAQ:TLRY) made an important step in its European operation by securing new cultivation rights in Germany.
The new Cannabis Act in Germany (MedCanG) will allow Tilray to significantly increase the production of its Aphria RX GmbH plant located in Berlin.
The news is important for this New York-based company, whose stock has fallen by 35 percent since April.
The new Tilray license
According to a press release issued by the company on Monday, this new license will increase Tilray’s medical cannabis production up to fivefold.
The expansion of Tilray’s stock is an important move that could help it recover. This license allows Tilray the ability to grow and produce 31 strains of approved cannabis.
Tilray will be able to expand their product line in Germany, and not just increase the genetic diversity.
Denise Faltischek (Tilray Chief Strategy Officer) highlighted the significance of this new license. She stated that it would allow “greater accessibility to some of Germany’s highest-quality medical cannabis.”
The company is now better positioned to take advantage of the growing German medical cannabis market.
Market response is positive and of strategic importance
Tilray stock was up approximately 3% when this article was written on Monday.
The increase in investor confidence is a reflection of the strategic decisions made by the company to enhance its manufacturing capabilities and strengthen its presence across Europe.
Tilray is about to release its earnings for the second quarter on July 29th. The license announcement comes at an important time.
This announcement may provide the much-needed boost to investor confidence ahead of earnings. The German Federal Institute for Drugs and Medical Devices, BfArM (BfArM), granted Aphria RX in 2019 the most comprehensive license for medical cannabis cultivation.
Tilray’s new license will allow it to take full advantage of this new market. The Cannabis Act in Germany has increased medical marijuana use by a significant amount.
Market expectations and financial outlook
Tilray has had a mixed recent performance financially. In the 4th quarter of 2023, the company was profitable per share. However, it is predicted to lose 2 cents in the next quarter.
Tilray has previously stated that it does not expect to achieve a positive free cash flow in 2024.
Zuanic & Associates analysts began covering Tilray in early July with a rating of “neutral”.
The company was cited as having the potential to gain from updates in regulatory requirements on overseas medical markets. Tilray could use this new license to take advantage of regulatory updates and boost its financial performance.
Tilray has taken a major step forward in its strategic expansion across Europe with the acquisition of a cannabis cultivation licence in Germany.
Tilray’s anticipated expansion in product variety and production capacity will allow it to take advantage of the growing German medical cannabis market.
This development, as the company prepares its earnings report for the second quarter, could restore investor confidence. It may also pave the path to future growth.
Watch here: https://www.youtube.com/embed/0UUrKOz49MA?feature=oembed
The post Tilray Secures New Cannabis Cultivation License in Germany: When is it Time to Buy TLRY? This post may change as new information is revealed
This site is for entertainment only. Click here to read more
